Alerts
PDF
Other content recommended for you
- Utilisation, expenditure and cost - effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
- Ivacaftor for cystic fibrosis
- New and emerging targeted therapies for cystic fibrosis
- Lumacaftor / ivacaftor for patients homozygous for Phe508del - CFTR: should we curb our enthusiasm
- Small molecule drugs in cystic fibrosis
- Progress in cystic fibrosis and the CF Therapeutics Development Network
- Response to: ‘ Lumacaftor / ivacaftor for patients homozygous for Phe508del - CFTR: should we curb our enthusiasm? ’ by Jones and Barry
- Parenteral nutrition: ethical and legal considerations
- Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding
- British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM - PD)